BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 71.8%

Neg 0% Neu 0% Pos 71.8%

BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.